June 4, 2023

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

Key Points

Key points are not available for this paper at this time.

Abstract

Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).

KI fragen

Bookmark

Cite This Study

Tsuboi et al. (Sun,) studied this question.

synapsesocial.com/papers/6941cf2d6ff23261fafbb7c7 https://doi.org/https://doi.org/10.1056/nejmoa2304594

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial2023 · 28 citations
2Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA22023 · 68 citations
3Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data2013 · 245 citations
4The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer2016 · 297 citations
5AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer2014 · 2,227 citations

KI fragen

Bookmark